Data / Drug companies / AvKARE
AvKARE: 290 products in the FDA NDC directory, labeler code 42291
AvKARE (labeler code 42291) lists 290 products in the FDA National Drug Code Directory, covering 129 finished drugs by generic name. By type: 287 prescription drugs, 3 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 26, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 42291
- Products in commercial distribution
- 290
- Packages
- 376
- Finished drugs by generic name
- 129
- Prescription products
- 287
- Over the counter products
- 3
- Controlled substance products
- Schedule II 6, Schedule III 1
- Flagged as original packager
- 88 of 88 products that carry the flag
- Started marketing in the last 12 months
- 12
- Products with a marketing end date set
- 2
- Earliest marketing start
- March 17, 2011
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 280 | 96.6% |
| New drug applications (NDA) | 6 | 2.1% |
| Over the counter monograph drugs | 2 | 0.7% |
| Authorized generics (NDA) | 1 | 0.3% |
| Other unapproved drugs | 1 | 0.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 287 | 99% |
| Over the counter drugs | 3 | 1% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 84 | 29% |
| Tablet, film coated | 66 | 22.8% |
| Capsule | 60 | 20.7% |
| Capsule, extended release | 16 | 5.5% |
| Tablet, film coated, extended release | 14 | 4.8% |
| Tablet, extended release | 12 | 4.1% |
| Tablet, delayed release | 6 | 2.1% |
| Tablet, coated | 4 | 1.4% |
| Kit | 4 | 1.4% |
| Tablet, orally disintegrating | 4 | 1.4% |
| Cream | 3 | 1% |
| Capsule, liquid filled | 2 | 0.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Dutasteride | 42291-257 | Capsule | Generic drugs (ANDA) | October 26, 2026 |
| Cephalexin | 42291-007 | Capsule | Generic drugs (ANDA) | April 24, 2026 |
| Cephalexin | 42291-006 | Capsule | Generic drugs (ANDA) | April 24, 2026 |
| Metaxalone | 42291-985 | Tablet | Generic drugs (ANDA) | March 4, 2026 |
| Metaxalone | 42291-985 | Tablet | Generic drugs (ANDA) | March 4, 2026 |
| Eltrombopag Olamine | 42291-935 | Tablet, film coated | Generic drugs (ANDA) | February 16, 2026 |
| Eltrombopag Olamine | 42291-934 | Tablet, film coated | Generic drugs (ANDA) | February 16, 2026 |
| Eltrombopag Olamine | 42291-933 | Tablet, film coated | Generic drugs (ANDA) | February 16, 2026 |
| Eltrombopag Olamine | 42291-932 | Tablet, film coated | Generic drugs (ANDA) | February 16, 2026 |
| Ondansetron | 42291-458 | Tablet, orally disintegrating | Generic drugs (ANDA) | November 17, 2025 |
| Ondansetron | 42291-457 | Tablet, orally disintegrating | Generic drugs (ANDA) | November 17, 2025 |
| Tamsulosin Hydrochloride | 42291-989 | Capsule | Generic drugs (ANDA) | November 16, 2025 |
| Zolmitriptan OD | 42291-999 | Tablet, orally disintegrating | Generic drugs (ANDA) | September 17, 2025 |
| Zolmitriptan OD | 42291-998 | Tablet, orally disintegrating | Generic drugs (ANDA) | September 17, 2025 |
| Risperidone | 42291-979 | Tablet, film coated | Generic drugs (ANDA) | August 27, 2025 |
| Risperidone | 42291-978 | Tablet, film coated | Generic drugs (ANDA) | August 27, 2025 |
| Risperidone | 42291-977 | Tablet, film coated | Generic drugs (ANDA) | August 27, 2025 |
| Potassium Chloride | 42291-487 | Tablet, extended release | Generic drugs (ANDA) | August 8, 2025 |
| Vardenafil Hydrochloride | 42291-826 | Tablet | Generic drugs (ANDA) | July 28, 2025 |
| Emtricitabine and Tenofovir Disoproxil Fumarate | 42291-980 | Tablet, film coated | Generic drugs (ANDA) | July 1, 2025 |
| Lisdexamfetamine Dimesylate | 42291-041 | Capsule | Generic drugs (ANDA) | June 4, 2025 |
| Lisdexamfetamine Dimesylate | 42291-040 | Capsule | Generic drugs (ANDA) | June 4, 2025 |
| Lisdexamfetamine Dimesylate | 42291-039 | Capsule | Generic drugs (ANDA) | June 4, 2025 |
| Lisdexamfetamine Dimesylate | 42291-038 | Capsule | Generic drugs (ANDA) | June 4, 2025 |
| Lisdexamfetamine Dimesylate | 42291-037 | Capsule | Generic drugs (ANDA) | June 4, 2025 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.